Hyperuricemia Clinical Trials 2025: EMA, PDMA, FDA Approvals, Medication, Therapies, NICE Approval, NDA Approval, Mechanism of Action, Route of Administration, and Companies by DelveInsight

(Albany, United States) "Hyperuricemia Pipeline Insight, 2025" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Hyperuricemia Market.

As per DelveInsight's assessment, globally, Hyperuricemia pipeline constitutes 12+ key companies continuously working towards developing 15+ Hyperuricemia treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

The Hyperuricemia Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Request for sample report @ https://www.delveinsight.com/sample-request/hyperuricemia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Some of the key takeaways from the Hyperuricemia Pipeline Report:
• Hyperuricemia Companies across the globe are diligently working toward developing novel Hyperuricemia treatment therapies with a considerable amount of success over the years.
• Hyperuricemia companies working in the treatment market are LG Chem, Shanton Pharma, InventisBio Co., Ltd, Jiangsu HengRui Medicine Co., Ltd., Fuji Yakuhin Co., Ltd., Virchow Group, Sanofi, Kissei Pharmaceutical Co., Ltd, Getz Pharma, Ardea Biosciences, Inc., Urica Therapeutics Inc., Nuon Therapeutics, Inc., CymaBay Therapeutics, Inc., JW Pharmaceutical, Selecta Biosciences, Inc., and others, are developing therapies for the Hyperuricemia treatment
• Emerging Hyperuricemia therapies in the different phases of clinical trials are - Tigulixostat(LC350189), SAP-001, D-0120, SHR4640, FYU-981, TULY, Rasburicase, KUX-1151, Febuxostat, RDEA594, RDEA806, dontinurad, Tranilast, Arhalofenate, URC102, SEL-212, and others are expected to have a significant impact on the Hyperuricemia market in the coming years.
• In December 2024, Atom Therapeutics Co. Ltd, a clinical-stage biotechnology company focused on inflammatory and metabolic diseases, has entered into an exclusive commercialization agreement with a subsidiary of China Medical System Holdings Ltd (CMS). The collaboration grants CMS the rights to commercialize lingdolinurad (ABP-671), a novel oral URAT1 inhibitor for chronic gout and hyperuricemia, across mainland China, Hong Kong, and Macao.

Hyperuricemia Overview
Hyperuricemia is a medical condition characterized by elevated levels of uric acid in the blood, often resulting from either increased production or decreased excretion of uric acid. Hyperuricemia is commonly associated with gout, a painful form of inflammatory arthritis, but it can also contribute to kidney stones and chronic kidney disease. Hyperuricemia occurs due to a variety of factors including genetic predisposition, high-purine diets, obesity, certain medications, and underlying health conditions such as hypertension and diabetes.

Hyperuricemia diagnosis is typically confirmed through blood tests that measure serum uric acid levels. Hyperuricemia treatment involves lifestyle modifications, such as dietary changes and weight management, as well as pharmacological interventions like xanthine oxidase inhibitors (e.g., allopurinol and febuxostat) and uricosuric agents. Hyperuricemia management is crucial for preventing complications and improving long-term health outcomes. Hyperuricemia prevalence is increasing globally, driven by lifestyle factors and aging populations. Hyperuricemia awareness is essential for early detection and intervention.

Hyperuricemia research continues to explore new therapeutic targets and precision medicine approaches. Hyperuricemia can be asymptomatic in many cases, making routine screening important for at-risk individuals. Hyperuricemia, when properly managed, can significantly reduce the risk of gout attacks and renal complications, enhancing overall quality of life.

Get a Free Sample PDF Report to know more about Hyperuricemia Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/hyperuricemia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Emerging Hyperuricemia Drugs Under Different Phases of Clinical Development Include:
• Tigulixostat(LC350189): LG Chem
• SAP-001: Shanton Pharma
• D-0120: InventisBio Co., Ltd
• SHR4640: Jiangsu HengRui Medicine Co., Ltd.
• FYU-981: Fuji Yakuhin Co., Ltd.
• TULY: Virchow Group
• Rasburicase: Sanofi
• KUX-1151: Kissei Pharmaceutical Co., Ltd
• Febuxostat: Getz Pharma
• RDEA594: Ardea Biosciences, Inc.
• RDEA806: Ardea Biosciences, Inc.
• dontinurad: Urica Therapeutics Inc.
• Tranilast: Nuon Therapeutics, Inc.
• LC350189: LG Chem
• Arhalofenate: CymaBay Therapeutics, Inc.
• URC102: JW Pharmaceutical
• SEL-212: Selecta Biosciences, Inc.

Hyperuricemia Route of Administration
Hyperuricemia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

Hyperuricemia Molecule Type
Hyperuricemia Products have been categorized under various Molecule types, such as
• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

Hyperuricemia Pipeline Therapeutics Assessment
• Hyperuricemia Assessment by Product Type
• Hyperuricemia By Stage and Product Type
• Hyperuricemia Assessment by Route of Administration
• Hyperuricemia By Stage and Route of Administration
• Hyperuricemia Assessment by Molecule Type
• Hyperuricemia by Stage and Molecule Type

DelveInsight's Hyperuricemia Report covers around 15+ products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Further Hyperuricemia product details are provided in the report. Download the Hyperuricemia pipeline report to learn more about the emerging Hyperuricemia therapies
https://www.delveinsight.com/sample-request/hyperuricemia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Some of the key companies in the Hyperuricemia Therapeutics Market include:
Key companies developing therapies for Hyperuricemia are - Pfizer Inc, F. Hoffmann-La Roche Ltd, Mylan NV, Fresenius Kabi AG, Hikma Pharmaceuticals PLC, Novartis AG, Teva Pharmaceutical Industries Ltd., Bayer AG, Bristol Myers Squibb, GSK Plc, Sun Pharmaceutical Industries Ltd, Dr. Reddy's Laboratories Ltd, Endo International plc, and others.

Hyperuricemia Pipeline Analysis:
The Hyperuricemia pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Hyperuricemia with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Hyperuricemia Treatment.
• Hyperuricemia key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Hyperuricemia Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Hyperuricemia market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Hyperuricemia drugs and therapies
https://www.delveinsight.com/sample-request/hyperuricemia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Hyperuricemia Pipeline Market Drivers
• Increasing Prevalence of Hyperuricemia and Gout, Aging Population, Advancements in Drug Development, Improved Diagnostic Techniques, Rising Awareness and Education, Strategic Collaborations and Partnerships, are some of the important factors that are fueling the Hyperuricemia Market.

Hyperuricemia Pipeline Market Barriers
• However, High Cost of Treatment, Side Effects of Medications, Stringent Regulatory Requirements, Limited Awareness in Developing Regions, Patent Expirations, Slow Drug Development Process, and other factors are creating obstacles in the Hyperuricemia Market growth.

Scope of Hyperuricemia Pipeline Drug Insight
• Coverage: Global
• Key Hyperuricemia Companies: LG Chem, Shanton Pharma, InventisBio Co., Ltd, Jiangsu HengRui Medicine Co., Ltd., Fuji Yakuhin Co., Ltd., Virchow Group, Sanofi, Kissei Pharmaceutical Co., Ltd, Getz Pharma, Ardea Biosciences, Inc., Urica Therapeutics Inc., Nuon Therapeutics, Inc., CymaBay Therapeutics, Inc., JW Pharmaceutical, Selecta Biosciences, Inc., and others
• Key Hyperuricemia Therapies: Tigulixostat(LC350189), SAP-001, D-0120, SHR4640, FYU-981, TULY, Rasburicase, KUX-1151, Febuxostat, RDEA594, RDEA806, dontinurad, Tranilast, Arhalofenate, URC102, SEL-212, and others
• Hyperuricemia Therapeutic Assessment: Hyperuricemia current marketed and Hyperuricemia emerging therapies
• Hyperuricemia Market Dynamics: Hyperuricemia market drivers and Hyperuricemia market barriers

Request for Sample PDF Report for Hyperuricemia Pipeline Assessment and clinical trials
https://www.delveinsight.com/sample-request/hyperuricemia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Table of Contents
1. Hyperuricemia Report Introduction
2. Hyperuricemia Executive Summary
3. Hyperuricemia Overview
4. Hyperuricemia- Analytical Perspective In-depth Commercial Assessment
5. Hyperuricemia Pipeline Therapeutics
6. Hyperuricemia Late Stage Products (Phase II/III)
7. Hyperuricemia Mid Stage Products (Phase II)
8. Hyperuricemia Early Stage Products (Phase I)
9. Hyperuricemia Preclinical Stage Products
10. Hyperuricemia Therapeutics Assessment
11. Hyperuricemia Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Hyperuricemia Key Companies
14. Hyperuricemia Key Products
15. Hyperuricemia Unmet Needs
16 . Hyperuricemia Market Drivers and Barriers
17. Hyperuricemia Future Perspectives and Conclusion
18. Hyperuricemia Analyst Views
19. Appendix
20. About DelveInsight

Related Reports:
• Trigeminal Neuralgia Market Size: https://www.delveinsight.com/report-store/chronic-pain-market
• Ventricular Fibrillation Market: https://www.delveinsight.com/report-store/electrophysiology-devices-market
• Adamantinoma Market: https://www.delveinsight.com/blog/bone-cancer-treatment-market
• Healthcare Subscription Models: https://www.delveinsight.com/blog/subscription-model-in-healthcare
• Healthcare Competitive Benchmarking: https://www.delveinsight.com/consulting/competitive-benchmarking-services
• Capnography Device Market: https://www.delveinsight.com/report-store/capnography-devices-market
• Benefits Of Robotics In Healthcare: https://www.delveinsight.com/blog/robotics-in-healthcare
• Wound Irrigation Systems Market: https://www.delveinsight.com/report-store/wound-irrigation-systems-market?utm_source=Medgadget&utm_medium=pressrelease&utm_campaign=kupr
• Pulse Oximeter Market: https://www.delveinsight.com/report-store/pulse-oximeters-market
• Gaucher Disease Market: https://www.delveinsight.com/report-store/gauchers-disease-market
• Anti-cd274 Pd-l1 Antibody Pipeline: https://www.delveinsight.com/report-store/pd-1-and-pd-l1-inhibitors-competitive-landscape
• Apheresis Market: https://www.delveinsight.com/report-store/apheresis-market
• Atherectomy Devices Market: https://www.delveinsight.com/report-store/atherectomy-devices-market
• Hearing Implants Market: https://www.delveinsight.com/report-store/hearing-implants-market
• Menopause Market: https://www.delveinsight.com/report-store/menopause-market
• Ophthalmic Imaging Equipment Market: https://www.delveinsight.com/report-store/ophthalmic-imaging-equipment-market
• Aortic Aneurysm Stent Grafts Market: https://www.delveinsight.com/report-store/aortic-aneurysm-stent-grafts-market
• Blood Glucose Monitoring Systems Market: https://www.delveinsight.com/report-store/blood-glucose-monitoring-systems-market
• Chronic Lymphocytic Leukemia Cll Market: https://www.delveinsight.com/report-store/chronic-lymphocytic-leukemia-cll-market
• Healthcare Due Diligence Services: https://www.delveinsight.com/consulting/due-diligence-services
• Pressure Ulcers Market: https://www.delveinsight.com/report-store/pressure-ulcers-market
• Pulse Oximeters Market: https://www.delveinsight.com/report-store/pulse-oximeters-market
• Diabetic Foot Ulcers Dfus Market: https://www.delveinsight.com/report-store/diabetic-foot-ulcers-dfus-market
• Energy Based Aesthetic Devices Market: https://www.delveinsight.com/report-store/energy-based-aesthetic-devices-market
• Hepatitis B Virus Market: https://www.delveinsight.com/report-store/chronic-hepatitis-b-virus-market
• Minimal Residual Disease Market: https://www.delveinsight.com/report-store/minimal-residual-disease-market
• Vertigo Market: https://www.delveinsight.com/report-store/vertigo-market
• Chronic Hepatitis B Virus Market: https://www.delveinsight.com/report-store/chronic-hepatitis-b-virus-market
• Neuroprosthetics Market: https://www.delveinsight.com/blog/neuroprosthetics-market-analysis
• Non Alcoholic Fatty Liver Disease Nafld Market: https://www.delveinsight.com/report-store/non-alcoholic-fatty-liver-disease-nafld-market
• Palmar Hyperhidrosis Market: https://www.delveinsight.com/report-store/palmar-hyperhidrosis-market
• Acute Pain Market: https://www.delveinsight.com/report-store/acute-pain-market
• Automated External Defibrillators Market: https://www.delveinsight.com/report-store/external-defibrillators-market
• Dysthymia Market: https://www.delveinsight.com/report-store/persistent-depressive-disorder-market?utm_source=globenewswire&utm_medium=pressrelease&utm_campaign=spr
• Interbody Cages Market: https://www.delveinsight.com/report-store/interbody-cages-market
• Osteoarthritis Market: https://www.delveinsight.com/report-store/knee-osteoarthritis-market
• Palmar Hyperhidrosis Market Size: https://www.delveinsight.com/report-store/palmar-hyperhidrosis-market
• Wet-age Related Macular Degeneration Market: https://www.delveinsight.com/report-store/wet-age-related-macular-degeneration-wet-amd-market
• X Linked Hypophosphatemia Market: https://www.delveinsight.com/report-store/x-linked-hypophosphatemia-market
• Absssi Market Size: https://www.delveinsight.com/report-store/acute-bacterial-skin-and-skin-structure-infections-market
• Age-related Macular Degeneration Market: https://www.delveinsight.com/report-store/age-related-macular-degeneration-amd-market
• Androgenetic Alopecia Market: https://www.delveinsight.com/report-store/androgenetic-alopecia-market
• Arthroscopy Devices Market: https://www.delveinsight.com/report-store/arthroscopy-devices-market
• Artificial Kidney Market: https://www.delveinsight.com/report-store/artificial-kidney-market
• Carpal Tunnel Syndrome Market: https://www.delveinsight.com/report-store/carpal-tunnel-syndrome-market
• Central Pain Syndrome Market: https://www.delveinsight.com/report-store/central-pain-syndrome-market
• Cough Assisted Device Market: https://www.delveinsight.com/report-store/cough-assist-devices-market
• Duchenne Muscular Dystrophy Market: https://www.delveinsight.com/blog/duchenne-muscular-dystrophy-market
• Hearing Aid Devices Market: https://www.delveinsight.com/report-store/audiology-devices-market
• Neurovascular Devices Market: https://www.delveinsight.com/report-store/neurovascular-devices-interventional-neurology-market
• Prefilled Syringes Market: https://www.delveinsight.com/report-store/prefilled-syringes-market
• Xerostomia Market: https://www.delveinsight.com/report-store/xerostomia-market

Contact Us:
Ankit Nigam
Manager Marketing
info@delveinsight.com
+14699457679
https://www.delveinsight.com/consulting

About DelveInsight
DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.

This release was published on openPR.